Cysteine variants of alpha interferon-2

Details Cysteine variants of alpha interferon-2 Cysteine variants of alpha interferon-2

2004-06-10

2010-06-08

Landsman, Robert (Department: 1646)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Lymphokines, e.g., interferons, interlukins, etc.

C424S085700, C514S002600

Reexamination Certificate

active

07732572

ABSTRACT:
The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby.

REFERENCES:
patent: 4588585 (1986-05-01), Mark et al.
patent: 4678751 (1987-07-01), Goeddel
patent: 4921699 (1990-05-01), DeChiara et al.
patent: 5166322 (1992-11-01), Shaw et al.
patent: 5206344 (1993-04-01), Katre et al.
patent: 5208158 (1993-05-01), Bech et al.
patent: 5223407 (1993-06-01), Wong et al.
patent: 5382657 (1995-01-01), Karasiewicz et al.
patent: 5441734 (1995-08-01), Reichert et al.
patent: 5766897 (1998-06-01), Braxton
patent: 5849535 (1998-12-01), Cunningham et al.
patent: 5908621 (1999-06-01), Glue et al.
patent: 6042822 (2000-03-01), Gilbert et al.
patent: 6177074 (2001-01-01), Glue et al.
patent: 6250469 (2001-06-01), Kline
patent: 6362162 (2002-03-01), Rybak et al.
patent: 6461605 (2002-10-01), Cutler et al.
patent: 6472373 (2002-10-01), Albrecht
patent: 6524570 (2003-02-01), Glue et al.
patent: 6608183 (2003-08-01), Cox, III
patent: 6780613 (2004-08-01), Wells et al.
patent: 7270809 (2007-09-01), Cox, III
patent: 2004/0136955 (2004-07-01), Barker et al.
patent: 0185459 (1986-06-01), None
patent: 0312358 (1989-04-01), None
patent: 0355460 (1990-02-01), None
patent: 0 458 064 (1991-11-01), None
patent: 0612846 (1994-08-01), None
patent: WO 90/12874 (1990-11-01), None
patent: 93/06217 (1993-04-01), None
patent: WO 93/00109 (1993-07-01), None
patent: 94/01453 (1994-01-01), None
patent: WO 94/12219 (1994-06-01), None
patent: WO 94/22466 (1994-10-01), None
patent: WO 95/11987 (1995-05-01), None
patent: WO 95/32003 (1995-11-01), None
patent: WO 96/31537 (1996-10-01), None
patent: 99/03887 (1999-01-01), None
patent: 00/42175 (2000-07-01), None
patent: 01/87925 (2001-11-01), None
patent: WO 02/44717 (2002-06-01), None
DeChiara T.M. et al. Procedures for in vitro DNA mutagenesis of human leukocyte interferon sequences. Methods in Enzymology. 1986. vol. 119, No. 58, pp. 403-415.
Bazan,Immunology Today, 11:350-354 (1990).
Campbell et al.,J. Peptide Res., 49:527-537 (1997).
Cunningham et al.,Science, 243:1330-1336 (1989).
Goodson and Katre,Bio/Technology, 8:343-346 (1990).
Karpusas et al.,Proc. Natl. Acad. Sci. USA, 94:11813-11818 (1997).
Lowman and Wells,J. Mol. Biol., 234:564-578 (1993).
Mott and Compbell,Curr Opin Struct Biol, 5:114-121 (1995).
Radhakrishnan et al.,Structure, 4(12):1453-1463 (1996).
Sprang and Bazan,Curr. Opin. Struct. Biol., 3:815-827 (1993).
Wells,Ann. Rev. Biochem., 65:609-634 (1996).
Zalipsky,Adv. Drug Delivery Reviews, 16:157-182 (1995).
Valenzuela D. et al., “Is Sequence Conservation in Interferons Due to Selection for Functional Proteins.” Nature, vol. 313(21). pp. 698-700. Feb. 1985.
U.S. Appl. No. 11/857,399, filed Sep. 18, 2007, Cox.
Bazan et al., Science, vol. 257 No. 5068, pp. 410-413 (Jul. 1992).
Beilharz et al., J. Interferon Res., 6:677-685 (1986).
Black RJ, Am. J. Med. 102 39-44 (1997).
Bowie et al., Science, vol. 247 No. 4948, pp. 1306-1310 (Mar. 1990).
Cunningham BC, Wells JA. Science. 244:1081-5, (1989).
Evinger et al., J. Biol. Chem. 256(5):2113-2114 (1981).
Hu et al., Journal of Immunology. 167:1482-1489 (2001).
Nisbet et al., Biochem. Int., 11:301-309 (1985).
Olins P.O. et al: ‘Saturation muatgenesis of human interleukin-3’ Journal of Biological Chemistry vol. 270, No. 40, Oct. 6, 1996, pp. 23754-23760.
Tymms et al., Antiviral Res., 12:37-47 (1989).
Zurawaki et al. “Definition and spatial location of mouse interleukin-2 residues that interact with the heterotrmeric receptor”, Embo Journal 12, 5113-5119, 1993.
International Preliminary Examination Report for International (PCT) Patent Application No. PCT/US98/14497, mailed May 11, 1999.
International Search Report for International (PCT) Patent Application No. PCT/US98/14497, mailed Oct. 22, 1998.
Clark et al., J. Biol. Chem., 271 (36):21969-21977 (1996).
Sytkowski et al., Proc. Nat. Acad. Sci. USA, 95:1184-1188 (1998).
Watson JD, Molecular biology of the Gene 3rd edition, p. 337, W. A. Benjamin, Inc. Menlo Park, California, Reading, Massachusetts, London, Amsterdam, Don Mills, Ontario. Sydney, 1977, ISBN 0-8053-9609-8.
Cheetham et al., “Structure-function studies of human interferons-α: enhanced activity on human and murine cells”, Antiviral Research 15 (1991) 27-40.
Edge et al., “Interferon Analogues from Synthetic Genes: An Approach to Protein Structure-Activity Studies”, Interferon, vol. 7, pp. 1-46, 1986.
Lydon et al., “Immunochemical Mapping of α-2 Interferon”, Biochemistry 1985, 24, 4131-4141.

Affiliated with

Also associated with

Rating

Cysteine variants of alpha interferon-2 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cysteine variants of alpha interferon-2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cysteine variants of alpha interferon-2 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4163070